Clinical Trial

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The primary purpose of this study is to assess the safety and tolerability of single and multiple intravenous (IV) doses of GIGA-2339 in participants with chronic Hepatitis B Virus (HBV) infection.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2027-09 -> 2028-11 2026-05-23
minor Completion pushed: 2027-09 -> 2028-11 2026-05-23
Trial Details
NCT Number NCT07024641
Lead Sponsor GigaGen, Inc.
Conditions Hepatitis B Virus Infection
Enrollment 48 participants
Start Date 2024-11-13
Primary Completion 2028-11 (estimated)
Study Completion 2028-11 (estimated)
Updated on ClinicalTrials.gov 2026-07-17